Nadelmann ER, Yeh JE, Chen ST, et al. - Cancer treatment using immune checkpoint inhibitors (ICIs) results in many types of skin toxic effects, each with unique treatment choices beyond current published guidelines.

• Literature summarizing the effective management of cutaneous immune-related adverse events (cirAEs) in patients receiving ICIs for cancer are scarce.

• This systematic review included 138 eligible studies that reported on 879 cirAEs.

• The following subtypes of cirAEs developed: maculopapular, pruritus, lichenoid, immunobullous, psoriasiform, granulomatous, erythema multiforme or Stevens Johnson Syndrome, drug rash with eosinophilia and systemic symptoms, connective tissue disease, hair, oral, and miscellaneous.

• Common management approaches included topical corticosteroids and systemic immunomodulators, including oral/intravenous corticosteroids, antimetabolite agents, calcineurin inhibitors, and tumor necrosis factor–α inhibitors, as well as systemic antipruritics for symptomatic relief.